Quanterix Q3 revenue rises on Alzheimer's diagnostics business

Quanterix

10/11/2025 21:16

Overview

Quanterix Q3 revenue grows 12.3% yr/yr to $40.2 mln

Adjusted EBITDA loss widens to $11.9 mln due to acquisition charges

Company achieves key integration milestones from Akoya transaction

Outlook

Quanterix reiterates 2025 revenue guidance of $130 mln to $135 mln

Company expects 2025 adjusted cash usage of $34 mln to $38 mln

Quanterix expects to achieve cash flow breakeven in 2026

Result Drivers

REVENUE GROWTH - Quanterix achieved a 12.3% increase in revenue, despite challenging market conditions

COST SYNERGIES - Achieved $67 mln in cost synergies from Akoya transaction integration, contributing to a more scalable company

ALZHEIMER'S DIAGNOSTICS - Accelerating business with positive Medicare pricing and expanding partnerships in Asia

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$40.23 mln
Q3 Net Income
-$33.52 mln
Q3 Basic EPS
-$0.73
Q3 Gross Profit
$17.21 mln
Q3 Operating Expenses
$54.53 mln
Q3 Operating Income
-$37.33 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Quanterix Corp is $6.50, about 24% above its November 7 closing price of $4.94

Press Release: ID:nBw4sj61qa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)